Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib

BACKGROUND: This study evaluated soluble serum proteins as biomarkers to subset patients with metastatic colorectal cancer (mCRC) treated with chemotherapy±cediranib, a vascular endothelial growth factor (VEGF) signalling inhibitor (VEGFi). Exploring biomarkers at pre- and on-treatment may identify...

Descripción completa

Detalles Bibliográficos
Autores principales: Pommier, A J C, Shaw, R, Spencer, S K M, Morgan, S R, Hoff, P M, Robertson, J D, Barry, S T, Jürgensmeier, J M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200086/
https://www.ncbi.nlm.nih.gov/pubmed/25121956
http://dx.doi.org/10.1038/bjc.2014.436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4200086/
https://www.ncbi.nlm.nih.gov/pubmed/25121956
http://dx.doi.org/10.1038/bjc.2014.436

Ejemplares similares